In patients with a PD-L1 CPS 1-19 with high tumor burden and/or significant symptoms that can tolerate chemotherapy, we favor chemotherapy plus pembrolizumab as a standard of care treatment, to maximize potential response, which can translate directly into a quality-of-life benefit. Here, CD274 is linked to neoplasm.